I F Tannock

Summary

Affiliation: University of Toronto
Country: Canada

Publications

  1. ncbi request reprint Eradication of a disease: how we cured symptomless prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada M5G 2M9
    Lancet 359:1341-2. 2002
  2. ncbi request reprint Mathematics in the realm of lapatinib: 500 + 500 = 1,500?
    Bostjan Seruga
    J Clin Oncol 26:2940-2. 2008
  3. ncbi request reprint Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
    Licun Wu
    Department of Medical Oncology and Hematology and Division of Experimental Therapeutics, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cancer Res 65:2825-31. 2005
  4. ncbi request reprint Repopulation of cancer cells during therapy: an important cause of treatment failure
    John J Kim
    Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
    Nat Rev Cancer 5:516-25. 2005
  5. ncbi request reprint Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment
    Fiona P Downie
    Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Psychooncology 15:921-30. 2006
  6. pmc The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors
    Krupa J Patel
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    BMC Cancer 9:356. 2009
  7. pmc The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
    Carol M Lee
    Divisions of Applied Molecular Oncology and Medical Oncology and Hematology Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    BMC Cancer 10:255. 2010
  8. ncbi request reprint Collaborative clinical trials: quality or quantity?
    I F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Int J Radiat Oncol Biol Phys 49:339-43. 2001
  9. ncbi request reprint Tumor physiology and drug resistance
    I F Tannock
    Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, ON, Canada
    Cancer Metastasis Rev 20:123-32. 2001
  10. ncbi request reprint Cognitive impairment associated with chemotherapy for cancer: report of a workshop
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Clin Oncol 22:2233-9. 2004

Detail Information

Publications97

  1. ncbi request reprint Eradication of a disease: how we cured symptomless prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada M5G 2M9
    Lancet 359:1341-2. 2002
  2. ncbi request reprint Mathematics in the realm of lapatinib: 500 + 500 = 1,500?
    Bostjan Seruga
    J Clin Oncol 26:2940-2. 2008
  3. ncbi request reprint Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts
    Licun Wu
    Department of Medical Oncology and Hematology and Division of Experimental Therapeutics, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cancer Res 65:2825-31. 2005
    ..Our results suggest that repopulation of PTEN-negative cancer cells between courses of chemotherapy might be inhibited by CCI-779...
  4. ncbi request reprint Repopulation of cancer cells during therapy: an important cause of treatment failure
    John J Kim
    Department of Radiation Oncology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, ON M5G 2M9, Canada
    Nat Rev Cancer 5:516-25. 2005
    ..Strategies developed to overcome repopulation have improved clinical outcomes, and now new strategies to inhibit repopulation are emerging in parallel with advances in the understanding of underlying biological mechanisms...
  5. ncbi request reprint Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment
    Fiona P Downie
    Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Psychooncology 15:921-30. 2006
    ..Here we compare assessment of these symptoms using self-report questionnaires and a researcher-administered screen of cognitive function with the experience of women as revealed in a semi-structured interview...
  6. pmc The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors
    Krupa J Patel
    Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada
    BMC Cancer 9:356. 2009
    ..Here we evaluate the effect of PgP expression on doxorubicin distribution in vivo...
  7. pmc The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
    Carol M Lee
    Divisions of Applied Molecular Oncology and Medical Oncology and Hematology Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    BMC Cancer 10:255. 2010
    ..Poor distribution of some anticancer drugs in solid tumors may limit their anti-tumor activity...
  8. ncbi request reprint Collaborative clinical trials: quality or quantity?
    I F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Int J Radiat Oncol Biol Phys 49:339-43. 2001
    ..To review the merits of using the limited available resources--patients, money, clinical scientists, and ideas--in various types of clinical trial...
  9. ncbi request reprint Tumor physiology and drug resistance
    I F Tannock
    Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, ON, Canada
    Cancer Metastasis Rev 20:123-32. 2001
    ....
  10. ncbi request reprint Cognitive impairment associated with chemotherapy for cancer: report of a workshop
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Clin Oncol 22:2233-9. 2004
    ....
  11. ncbi request reprint Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
    Ian F Tannock
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    N Engl J Med 351:1502-12. 2004
    ..We compared such treatment with docetaxel plus prednisone in men with this disease...
  12. ncbi request reprint Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy
    Ian F Tannock
    Department of Medical Oncology and Hematology and the Division of Experimental Therapeutics, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, M5G 2M9 Canada
    Clin Cancer Res 8:878-84. 2002
    ....
  13. doi request reprint Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials
    Bostjan Seruga
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 29:174-85. 2011
    ..Here, we analyze adverse drug reactions (ADRs) of targeted anticancer agents from updated drug labels and their reporting in corresponding pivotal RCTs...
  14. doi request reprint When are "positive" clinical trials in oncology truly positive?
    Alberto Ocana
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
    J Natl Cancer Inst 103:16-20. 2011
    ....
  15. ncbi request reprint Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:1756-64. 1996
    ..To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial...
  16. pmc The chronic administration of drugs that inhibit the regulation of intracellular pH: in vitro and anti-tumour effects
    M Yamagata
    Department of Medicine, Ontario Cancer Institute, University of Toronto, Canada
    Br J Cancer 73:1328-34. 1996
    ..002 at tolerated doses of the four drugs used to treat KHT tumours. The experiments demonstrate the activity of drugs that inhibit the regulation of pHi against murine tumours when delivered by chronic infusion...
  17. pmc Inhibition of the regulation of intracellular pH: potential of 5-(N,N-hexamethylene) amiloride in tumour-selective therapy
    J Luo
    Department of Medicine, Ontario Cancer Institute, Toronto, Canada
    Br J Cancer 70:617-24. 1994
    ..Acid-mediated therapy can lead to cell death in murine solid tumours, but further measures will be required before the strategy can be exploited clinically...
  18. ncbi request reprint A retrospective analysis of the relationship between changes in serum PSA, palliative response and survival following systemic treatment in a Canadian randomized trial for symptomatic hormone-refractory prostate cancer
    A J Dowling
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Ontario, Canada
    Ann Oncol 12:773-8. 2001
    ..PSA response was associated with longer survival. Patients treated with M + P were more likely to achieve a PSA response and a palliative response than those treated with P...
  19. doi request reprint Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: a prospective controlled study
    H G Mar Fan
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Ann Oncol 21:983-7. 2010
    ..Women with breast cancer frequently undergo menopause following adjuvant chemotherapy. Here, we investigated whether they have more severe symptoms than women undergoing natural menopause...
  20. pmc Evidence against apoptosis as a major mechanism for reproductive cell death following treatment of cell lines with anti-cancer drugs
    I F Tannock
    Dept of Medical Oncology and Haematology and the Division of Experimental Therapy, Ontario Cancer Institute and Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Br J Cancer 84:100-5. 2001
    ..When apoptosis is observed following treatment with anti-cancer drugs it may be a secondary event which occurs in lethally-damaged cells, leading to their lysis, rather than a primary event that leads to loss of reproductive integrity...
  21. doi request reprint Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa
    D R Berthold
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Ann Oncol 19:1749-53. 2008
    ..At progression, many patients were treated with the other drug. Here, we provide a retrospective report of survival and prostate-specific antigen (PSA) response after second-line therapy...
  22. ncbi request reprint Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer
    P P Leung
    Department of Pharmaceutical Services, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 17:3082-90. 1999
    ..A cost-utility analysis was therefore performed to create a rank order on the basis of effectiveness, quality of life, and economic considerations...
  23. pmc Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment
    A R Karuri
    Division of Experimental Therapeutics, Ontario Cancer Institute, Toronto, Canada
    Br J Cancer 68:1080-7. 1993
    ..Weak acids that are normal cellular metabolites are not toxic in vivo, but weak acids carrying cytotoxic groups offer the potential for selective uptake and toxicity under the conditions of low pHe that exist in many solid tumours...
  24. ncbi request reprint Factors that influence the penetration of methotrexate through solid tissue
    D S Cowan
    Department of Medicine, Ontario Cancer Institute and University of Toronto, Ontario, Canada
    Int J Cancer 91:120-5. 2001
    ..Our data provide evidence that tissue penetration of methotrexate is through the extracellular space, that its distribution in solid tissue may be limited and that it may be possible to improve its tissue penetration...
  25. pmc Inhibition of endosomal sequestration of basic anticancer drugs: influence on cytotoxicity and tissue penetration
    C M Lee
    Division of Applied Molecular Oncology, Princess Margaret Hospital University of Toronto, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Br J Cancer 94:863-9. 2006
    ..We conclude that modifiers of endosomal pH might increase therapeutic effectiveness of basic drugs by increasing their toxicity and/or tissue penetration in solid tumours...
  26. doi request reprint Global drug development in cancer: a cross-sectional study of clinical trial registries
    B Seruga
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    Ann Oncol 21:895-900. 2010
    ..Correlations were sought between the number of clinical trials and incidence, mortality and prevalence of the cancers studied (obtained from GLOBOCAN 2002) and stratified by region of the world...
  27. doi request reprint Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study
    Dominik R Berthold
    FRCPC, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Clin Oncol 26:242-5. 2008
    ..Here, we report an updated analysis of survival...
  28. doi request reprint The influence of erythropoietin on cognitive function in women following chemotherapy for breast cancer
    H G Mar Fan
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Psychooncology 18:156-61. 2009
    ..Here, we report a non-randomized sub-study in which cognitive function of participants was evaluated at 12-30 months after chemotherapy...
  29. doi request reprint Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer
    B Seruga
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Ann Oncol 21:1411-8. 2010
    ..Phase III randomized clinical trials (RCTs) have become larger and are powered to detect small absolute benefits. Temporal changes in absolute benefits of experimental medical therapies reported in RCTs are unknown...
  30. pmc Regulation of intracellular pH in subpopulations of cells derived from spheroids and solid tumours
    M J Boyer
    Department of Medicine, Ontario Cancer Institute, Toronto, Canada
    Br J Cancer 68:890-7. 1993
    ..Our results suggest the feasibility of pharmacological inhibition of Na+/H+ exchange activity as an approach to therapy directed against nutrient-deprived tumour cells...
  31. ncbi request reprint Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma
    C Mayers
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cancer 91:2246-57. 2001
    ..Classic CMF should be used when this regimen is selected for adjuvant treatment, and dose adjustment resulting in moderate myelosuppression should be explored in future clinical trials...
  32. ncbi request reprint Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost
    S A McLachlan
    Department of Medicine, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Canada
    Breast Cancer Res Treat 54:213-23. 1999
    ....
  33. ncbi request reprint Death of tumor cells after intracellular acidification is dependent on stress-activated protein kinases (SAPK/JNK) pathway activation and cannot be inhibited by Bcl-2 expression or interleukin 1beta-converting enzyme inhibition
    B W Zanke
    Department of Medicine, The Princess Margaret Hospital and the Ontario Cancer Institute, Toronto, Canada
    Cancer Res 58:2801-8. 1998
    ..We conclude that acid-induced cell death depends on bax and on SAPK signaling pathways, but not on the caspase proteases. Therapeutic manipulation of bax and SAPK may enhance acid-induced tumor cell killing...
  34. ncbi request reprint Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer
    M J Moore
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 15:3441-5. 1997
    ..To evaluate the efficacy and toxicity of gemcitabine (2',2'-difluorodeoxycytidine) in previously untreated patients with advanced transitional cell carcinoma...
  35. pmc Therapeutic potential of analogues of amiloride: inhibition of the regulation of intracellular pH as a possible mechanism of tumour selective therapy
    R P Maidorn
    Department of Medical Biophysics, Ontario Cancer Institute, University of Toronto, Canada
    Br J Cancer 67:297-303. 1993
    ....
  36. ncbi request reprint Impact of androgen deprivation therapy on physical and cognitive function, as well as quality of life of patients with nonmetastatic prostate cancer
    F Joly
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Avenue, Toronto, Ontario, Canada
    J Urol 176:2443-7. 2006
    ..We compared physical and cognitive function, and quality of life in a cross-sectional study of 57 patients receiving androgen deprivation therapy for nonmetastatic prostate cancer and 51 healthy age matched controls...
  37. doi request reprint A randomized double-blind placebo-controlled cross-over trial of the impact on quality of life of continuing dexamethasone beyond 24 h following adjuvant chemotherapy for breast cancer
    J Vardy
    Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Breast Cancer Res Treat 136:143-51. 2012
    ..No other symptom/QOL domains differed significantly. In conclusion, no significant difference was found in patient preference, QOL, or symptoms regardless of whether dexamethasone or placebo was used after adjuvant chemotherapy...
  38. pmc Is there a role for chemotherapy in prostate cancer?
    C M Canil
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Br J Cancer 91:1005-11. 2004
    ..Large phase III trials comparing docetaxel with mitoxantrone have completed accrual. There is no role for chemotherapy in earlier stages of disease except in the context of a well-designed clinical trial...
  39. ncbi request reprint Assessment of tumor cell repopulation after chemotherapy for advanced ovarian cancer: pilot study
    A J Davis
    Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cytometry A 51:1-6. 2003
    ..Given the longer intervals between cycles and longer total duration of treatment, the impact of repopulation is likely to be greater after chemotherapy...
  40. ncbi request reprint Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer
    Nadine Tchen
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    J Clin Oncol 21:4175-83. 2003
    ..Here, we determine their incidence and severity, and interrelationships between them and quality of life...
  41. ncbi request reprint Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma
    Brigette B Y Ma
    Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada
    Cancer 95:2516-23. 2002
    ..Results from Phase II trials conducted in Asia have shown that gemcitabine alone (GEM) or with cisplatin (GC) is active among patients with metastatic or locally recurrent nasopharyngeal carcinoma (NPC)...
  42. ncbi request reprint Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and radiotherapy for breast carcinoma: a well tolerated adjuvant regimen
    Neil Isaac
    Department of Radiation Oncology, Princess Margaret Hospital University Health Network and University of Toronto, Toronto, Ontario, Canada
    Cancer 95:696-703. 2002
    ..The current study was conducted to assess the toxicity of concurrent adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy and radiotherapy (RT) for early breast carcinoma...
  43. ncbi request reprint Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study
    Helen G Mar Fan
    Princess Margaret Hospital and University of Toronto, Ontario, Canada
    J Clin Oncol 23:8025-32. 2005
    ..We previously evaluated fatigue, menopausal symptoms, and cognitive dysfunction in patients receiving adjuvant therapy for breast cancer and matched healthy women. Here we report assessment of these women 1 and 2 years later...
  44. doi request reprint How valid are claims for synergy in published clinical studies?
    A Ocana
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Ann Oncol 23:2161-6. 2012
    ..Clinical trials evaluating drug combinations are often stimulated by claims of synergistic interactions in preclinical models. Overuse or misuse of the term synergy could lead to poorly designed clinical studies...
  45. pmc Cytostatic potential of novel agents that inhibit the regulation of intracellular pH
    P Wong
    Department of Medical Biophysics, Princess Margaret Hospital Ontario Cancer Institute, University of Toronto, Toronto, M5G 2M9, Canada
    Br J Cancer 87:238-45. 2002
    ..Our results indicate that cariporide and S3705 are selective cytostatic agents under in vitro conditions that reflect the slightly acidic microenvironment found in solid tumours...
  46. pmc pH dependent cytotoxicity of N-dodecylimidazole: a compound that acquires detergent properties under acidic conditions
    M J Boyer
    Department of Medicine, Ontario Cancer Institute, Toronto, Canada
    Br J Cancer 67:81-7. 1993
    ....
  47. pmc The contribution of lactic acid to acidification of tumours: studies of variant cells lacking lactate dehydrogenase
    M Yamagata
    Department of Medicine and Medical Biophysics, Ontario Cancer Institute Princess Margaret Hospital, Toronto, Canada
    Br J Cancer 77:1726-31. 1998
    ....
  48. ncbi request reprint A Phase II trial of docetaxel and cisplatin in patients with recurrent or metastatic nasopharyngeal carcinoma
    J S McCarthy
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Oral Oncol 38:686-90. 2002
    ..Grade 3-4 neutropenia was observed in all (100%) patients over 93% of the treatment cycles, and in three cases this was complicated by fever. Other toxicities were mild...
  49. ncbi request reprint A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma
    Monika K Krzyzanowska
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
    Cancer Chemother Pharmacol 60:135-41. 2007
    ..The lack of effective systemic therapies for patients with advanced renal cell carcinoma (RCC) has stimulated interest in evaluating novel treatment strategies for this disease...
  50. ncbi request reprint Assessing cognitive function in cancer patients
    Janette Vardy
    Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
    Support Care Cancer 14:1111-8. 2006
    ..Some patients with cancer suffer cognitive impairment after chemotherapy. A brief, sensitive instrument is required to screen patients for cognitive impairment. In this study, we compare three possible screening instruments...
  51. ncbi request reprint Long-term outcome of radiation-based conservation therapy for invasive bladder cancer
    Peter W M Chung
    Department of Radiation Oncology, Princess Margaret Hospital, University Health Network and University of Toronto, Toronto, Ontario M5G 2M9, Canada
    Urol Oncol 25:303-9. 2007
    ..To report the long-term results and examine factors associated with bladder preservation, risk of relapse, and survival in patients treated with radical radiotherapy for invasive bladder cancer...
  52. pmc Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy
    J Vardy
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, 610 University Ave, Toronto, Ontario, Canada M5G2M9
    Br J Cancer 94:1011-5. 2006
    ..A randomised, double-blind crossover trial is underway to determine the effect of dexamethasone on nausea and vomiting, and the impact of side effects of dexamethasone and of nausea and vomiting on quality of life...
  53. doi request reprint The changing face of hormonal therapy for prostate cancer
    B Seruga
    Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Ann Oncol 19:vii79-85. 2008
  54. ncbi request reprint A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancer
    Helen G Mar Fan
    Princess Margaret Hospital and University of Toronto, 610 University Ave, Suite 5 218, Toronto, Ontario, M5G 2M9, Canada
    Support Care Cancer 16:577-83. 2008
    ..Women who receive adjuvant chemotherapy for breast cancer develop fatigue, and a subset reports cognitive impairment. Methylphenidate is reported to improve fatigue and to decrease cognitive impairment in other populations...
  55. ncbi request reprint Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research
    Janette Vardy
    Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:2455-63. 2007
    ..There is evidence that some cancer survivors suffer cognitive impairment after chemotherapy. Determining if a patient has cognitive impairment is challenging, especially because impairment is usually subtle...
  56. ncbi request reprint Serum lipids and outcome of early-stage breast cancer: results of a prospective cohort study
    Mala Bahl
    The Samuel Lunenfeld Research Institute and Department of Medicine, Mount Sinai Hospital, Toronto, ON, Canada
    Breast Cancer Res Treat 94:135-44. 2005
    ..Here, we examine whether serum levels of total cholesterol (TC) and triglycerides (TG) influence breast cancer outcome...
  57. ncbi request reprint Doctor's dilemma: incorporating tumor markers into clinical decision-making
    Christina M Canil
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, University Health Network, Toronto, Ontario, Canada
    Semin Oncol 29:286-93. 2002
    ....
  58. ncbi request reprint Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil
    Licun Wu
    Division of Experimental Therapeutics and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Ontario, M5G 2M9 Canada
    Cancer Res 63:2134-8. 2003
    ..05 for each comparison). Accelerating repopulation after sequential treatments with cyclophosphamide or 5FU can lead to effective drug resistance in the absence of changes in the sensitivity of constituent cells...
  59. doi request reprint Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts
    Andrea S Fung
    Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    Clin Cancer Res 15:5389-95. 2009
    ..We compared the effects of concurrent and sequential administration of chemotherapy and the mammalian target of rapamycin (mTOR) inhibitor temsirolimus (CCI-779) on tumor cells and xenografts...
  60. doi request reprint Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer
    F E Vera-Badillo
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Canada
    Ann Oncol 24:1238-44. 2013
    ..Here, we evaluate the quality of reporting of the primary end point (PE) and of toxicity in RCTs for breast cancer...
  61. ncbi request reprint Treatment of cancer with radiation and drugs
    I F Tannock
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    J Clin Oncol 14:3156-74. 1996
    ..To review the current status and future prospects of combined treatment of cancer with radiation and drugs...
  62. pmc Quality of life and understanding of disease status among cancer patients of different ethnic origin
    N Tchen
    Princess Margaret Hospital and University of Toronto, 610 University Avenue, Toronto, Canada M5G 2M9
    Br J Cancer 89:641-7. 2003
    ..001 for Italian vs other groups). Performance status was correlated with QoL and most closely related with the extent of disease. Understanding of cultural differences is important for optimal management of patients with cancer...
  63. ncbi request reprint Tumor physiology and resistance to chemotherapy: repopulation and drug penetration
    Alison J Davis
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    Cancer Treat Res 112:1-26. 2002
  64. ncbi request reprint Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy
    Wu Licun
    Division of Experimental Therapeutics and Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario M5G 2M9 Canada
    Clin Cancer Res 9:4614-8. 2003
    ..Here we study inhibition of repopulation of hormone-responsive human breast cancer cell lines by selective estrogen receptor (ER) modulators (SERMs) during courses of chemotherapy...
  65. pmc Evolution of the randomized controlled trial in oncology over three decades
    Christopher M Booth
    National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
    J Clin Oncol 26:5458-64. 2008
    ..The randomized controlled trial (RCT) is the gold standard for establishing new therapies in clinical oncology. Here we document changes with time in design, sponsorship, and outcomes of oncology RCTs...
  66. doi request reprint The hypoxia-activated ProDrug AQ4N penetrates deeply in tumor tissues and complements the limited distribution of mitoxantrone
    Olivier Tredan
    Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Cancer Res 69:940-7. 2009
    ..This study supports clinical evaluation of AQ4N in combination with conventional anticancer agents, such as mitoxantrone...
  67. ncbi request reprint The role of systemic chemotherapy in the management of muscle-invasive bladder cancer
    Helen G Juffs
    Princess Margaret Hospital, Ontario, Toronto, Canada
    Lancet Oncol 3:738-47. 2002
    ..Other trials should address the role of molecular markers in selecting patients for chemotherapy. Whenever possible, chemotherapy for locally advanced muscle-invasive TCC should be given in the context of a well-designed clinical trial...
  68. ncbi request reprint "PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer
    Aisha Lofters
    Department of Medical Oncology, Princess Margaret Hospital and University of Toronto, Ontario, Canada
    J Urol 168:2516-20. 2002
    ..High or increasing prostatic specific antigen (PSA) levels may be a source of anxiety in patients with metastatic prostate cancer...
  69. ncbi request reprint Drug resistance and the solid tumor microenvironment
    Olivier Tredan
    Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON M5G 2M9, Canada
    J Natl Cancer Inst 99:1441-54. 2007
    ....
  70. ncbi request reprint The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells
    Rama Grantab
    Division of Applied Molecular Oncology and Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Toronto, Ontario, Canada M5G 2M9
    Cancer Res 66:1033-9. 2006
    ....
  71. pmc Are treatment strategies of urologic oncologists influenced by the opinions of their colleagues?
    M J Moore
    Department of Medicine, Princess Margaret Hospital, Toronto, Canada
    Br J Cancer 62:988-91. 1990
    ..We conclude that treatment strategies of urologic oncologists are influenced minimally by opinions of their colleagues, but that the method of using surrogate questionnaires is a valuable aid to the design of clinical trials...
  72. pmc Tumour response to chemotherapy in animals that have been treated with the same drugs prior to tumour implantation: a model for studying host effects on apparent drug resistance
    C K Luk
    Physics Division, Ontario Cancer Institute, Toronto, Canada
    Br J Cancer 58:133-8. 1988
    ..Our results indicate that cyclophosphamide produces only a small effect on the host in this system, but the model is a potentially useful one to investigate the contribution of the host in the acquisition of drug resistance...
  73. ncbi request reprint Quality of cancer care
    J Vardy
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
    Ann Oncol 15:1001-6. 2004
    ..Treatment of the whole patient requires attention to communication, and to the management of symptoms such as pain and fatigue. Cancer care must be of high quality and delivered with compassion...
  74. doi request reprint Phase II trial of mirtazapine for cancer-related cachexia and anorexia
    Rachel P Riechelmann
    Department of Medical Oncology, University of Toronto, Canada
    Am J Hosp Palliat Care 27:106-10. 2010
    ..2 kg); 24% and 6% improved appetite and health-related quality of life (HQOL), respectively. Mirtazapine is a promising agent for the treatment of CRCA...
  75. ncbi request reprint Management of advanced prostate cancer after first-line chemotherapy
    Dominik R Berthold
    Department of Medical Oncology, Princess Margaret Hospital, and University of Toronto, Ontario M5G 2M9, Canada
    J Clin Oncol 23:8247-52. 2005
    ....
  76. ncbi request reprint Potential drug interactions and duplicate prescriptions among cancer patients
    Rachel P Riechelmann
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
    J Natl Cancer Inst 99:592-600. 2007
    ..Cancer patients receive numerous medications, including antineoplastic agents, drugs for supportive care, and medications for comorbid illnesses. Therefore, they are at risk for drug interactions and duplicate prescribing...
  77. doi request reprint Sorafenib for metastatic renal cancer: the Princess Margaret experience
    Rachel P Riechelmann
    Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Am J Clin Oncol 31:182-7. 2008
    ..Grade 3/4 adverse events were reported in 12% of patients. This study presents sorafenib's efficacy and safety in a less selected cohort of patients enrolled in an expanded access program...
  78. ncbi request reprint The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors
    Andrew J Primeau
    Division of Applied Molecular Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 11:8782-8. 2005
    ..Here, we study the distribution of doxorubicin in relation to blood vessels and regions of hypoxia in solid tumors of mice...
  79. ncbi request reprint Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy
    Licun Wu
    Division of Experimental Therapeutics, Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    Clin Cancer Res 11:8195-200. 2005
    ..The scheduling of short-acting hormonal agents between courses of adjuvant chemotherapy for human breast cancer has potential to improve the outcome of treatment...
  80. ncbi request reprint Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings
    Philippe L Bedard
    Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
    J Clin Oncol 25:3482-7. 2007
    ..To investigate the prevalence of underpowered randomized controlled trials (RCTs) presented at American Society of Clinical Oncology (ASCO) annual meetings...
  81. doi request reprint Chemotherapy-based treatment for castration-resistant prostate cancer
    Bostjan Seruga
    Institute of Oncology Ljubljana, Ljubljana, Slovenia
    J Clin Oncol 29:3686-94. 2011
    ....
  82. ncbi request reprint Low-dose prophylactic platelet transfusions in recipients of an autologous peripheral blood progenitor cell transplant and patients with acute leukemia: a randomized controlled trial with a sequential Bayesian design
    Alan Tinmouth
    Department of Hematology and Oncology, Princess Margaret Hospital and University of Toronto, Toronto, Ontario, Canada
    Transfusion 44:1711-9. 2004
    ..A randomized controlled trial was undertaken to examine the effectiveness of low-dose PLT transfusions and to determine the need for further studies...
  83. ncbi request reprint Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status
    Mala Bahl
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada
    Int J Radiat Oncol Biol Phys 60:1127-36. 2004
    ..The Intergroup 0099 trial (INT 0099) for locally advanced nasopharyngeal cancer (NPC) has set a standard of practice. This retrospective review documents our institutional experience with this regimen...
  84. ncbi request reprint Reduction of intracellular pH as a strategy to enhance the pH-dependent cytotoxic effects of melphalan for human breast cancer cells
    Philip Wong
    Department of Medical Biophysics and Medical Oncology, Princess Margaret Hospital Ontario Cancer Institute, University of Toronto, Toronto, Ontario, Canada
    Clin Cancer Res 11:3553-7. 2005
    ..Although these results add to evidence that manipulation of intracellular pH within the acidic environment of solid tumors can influence the effects of chemotherapy, they are too small and inconsistent to warrant clinical evaluation...
  85. doi request reprint Cytokines and their relationship to the symptoms and outcome of cancer
    Bostjan Seruga
    Division of Medical Oncology, Princess Margaret Hospital, St Michael s Hospital, University of Toronto, Toronto, Canada
    Nat Rev Cancer 8:887-99. 2008
    ..However, physical activity might modify cytokine levels and decrease fatigue in patients with cancer, and might also improve their prognosis...
  86. pmc Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer
    Ignacio Duran
    Department of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada
    J Gen Intern Med 21:C6-8. 2006
    ..We discuss the pathogenesis, differential diagnosis, and association of DIC with prostate cancer along with the management of this condition...
  87. ncbi request reprint Should screen-detected breast cancers be managed differently?
    Monika K Krzyzanowska
    J Natl Cancer Inst 97:1170-1. 2005
  88. ncbi request reprint Placebo effects in oncology
    Gisèle Chvetzoff
    Department of Medical Oncology, Centre Leon Berard, Lyon, France
    J Natl Cancer Inst 95:19-29. 2003
    ..We hypothesized that administration of placebos would improve symptom control and quality of life but would not lead to tumor response...
  89. ncbi request reprint Scheduling of radiation and chemotherapy for limited-stage small-cell lung cancer: repopulation as a cause of treatment failure?
    Anthony M Brade
    J Clin Oncol 24:1020-2. 2006
  90. ncbi request reprint A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis
    Andrew J Armstrong
    Duke Comprehensive Cancer Center, Durham, North Carolina 27705, USA
    Clin Cancer Res 13:6396-403. 2007
    ..To develop a prognostic model and nomogram using baseline clinical variables to predict death among men with metastatic hormone-refractory prostate cancer (HRPC)...
  91. ncbi request reprint Postoperative radiotherapy for breast cancer: growing evidence for an impact on survival
    Katherine A Vallis
    J Natl Cancer Inst 96:88-9. 2004
  92. ncbi request reprint Drug penetration in solid tumours
    Andrew I Minchinton
    Department of Medical Biophysics, British Columbia Cancer Research Centre, Vancouver, Canada
    Nat Rev Cancer 6:583-92. 2006
    ....
  93. ncbi request reprint Screening trials are even more difficult than we thought they were
    Helen G Juffs
    J Natl Cancer Inst 94:156-7. 2002
  94. ncbi request reprint Trials in palliative treatment--have the goal posts been moved?
    Peter Kirkbride
    Weston Park Hospital, Sheffield, UK
    Lancet Oncol 9:186-7. 2008
  95. ncbi request reprint Should bisphosphonates be used routinely in patients with prostate cancer metastatic to bone?
    Christina M Canil
    J Natl Cancer Inst 94:1422-3. 2002
  96. ncbi request reprint Ethics in oncology: consulting for the investment industry
    Jordan Berlin
    Vanderbilt University Medical Center, Nashville, TN, USA
    J Clin Oncol 25:444-6. 2007
    ..Because these columns are intended to address the concerns of ASCO members, the Committee welcomes suggestions for future topics at vignettes@asco.org. Martin D. Abeloff, MD, Chair, Ethics Committee...
  97. ncbi request reprint Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation
    Eric X Chen
    JAMA 292:2150-1. 2004